All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the Lymphoma Hub spoke to David J. Straus, Memorial Sloan Kettering Cancer Center, New York, US. We asked: What’s current and what’s next in Hodgkin lymphoma?
What’s current and what’s next in Hodgkin lymphoma?
David J. Straus covers radio- and chemotherapy-based approaches, and outlines a number of novel drug classes that have demonstrated favorable responses in patients with Hodgkin lymphoma.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox